Q1 EPS Estimate for Elanco Animal Health Reduced by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a report released on Monday, April 21st. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings of $0.28 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.78 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.09 EPS and FY2028 earnings at $1.29 EPS.

Several other equities research analysts also recently weighed in on the company. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Piper Sandler reduced their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Barclays lowered their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Finally, UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.67.

Elanco Animal Health Stock Up 3.5 %

Shares of NYSE ELAN opened at $9.20 on Wednesday. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.80. The firm has a 50-day simple moving average of $10.10 and a two-hundred day simple moving average of $11.73. The company has a market cap of $4.57 billion, a P/E ratio of 23.00, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently added to or reduced their stakes in ELAN. Steward Partners Investment Advisory LLC lifted its position in shares of Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $124,000 after buying an additional 2,264 shares during the last quarter. DDD Partners LLC purchased a new stake in Elanco Animal Health during the fourth quarter valued at approximately $5,974,000. Harbor Capital Advisors Inc. boosted its stake in Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after acquiring an additional 209,734 shares in the last quarter. Franklin Resources Inc. grew its holdings in Elanco Animal Health by 14.0% in the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after purchasing an additional 45,795 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after purchasing an additional 2,059 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the acquisition, the director now owns 101,459 shares of the company’s stock, valued at $1,105,903.10. The trade was a 10.93 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.89% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.